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I. ABSTRACT
Vitamin K epoxide reductase complex subunit 1 (VKORC1) plays a central
role in ?-carboxylation – an important biological process. During ?-
carboxylation glutamic acid residues are carboxylated to ?-
carboxyglutamate (Gla). Several proteins, among them osteocalcin, are
only functionally active after ?-carboxylation, a vitamin K dependet
process. In the ?-carboxylation process, vitamin K  is converted to vitamin
K epoxide, which needs to be recycled to vitamin K by reduction. VKOR is
centrally involved in this process.
VKORC1 is highly polymorphic, and SNPs have been identified in the
promoter, the coding and the 3´-region of the gene. The -1639G>A
promoter polymorphism is a functional SNP in VKORC1 and the A allele is
associated with a significant decrease of VKORC1 promoter activity and
with a 2-fold lower mRNA expression (reported for liver cells). In this
study, the influence of the -1639G>A polymorphism in the VKORC1
promoter on the promoter activity in osteoblasts was studied using a dual
luciferase reporter gene assay.
Two transfection methods were compared: Lipofectamine 2000 and
Metafectene Pro. While transfection with Lipofectamine 2000 was not
suitable  Metafectene Pro was successful. Following transfection of
osteoblasts with Metafectene the reporter gene assay indicated a 43%
higher activity of the promoter carrying the G at position -1639 compared
to the A variant. This is in agreement with the results reported for liver
cells.
An analysis of the impact of the promoter G and A variants on the
expression of VKORC1 mRNA in osteoblasts was attempted. However,
the experiments were not successful, and further studies will be necessary
to answer this question.
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II. ZUSAMMENFASSUNG
Vitamin K Epoxid Reduktase Untereinheit 1 (VKORC1) ist ein Gen, dass
eine zentrale Rolle bei dem wichtigen biologischen Prozess der
?-Carboxylierung spielt. Die ?-Carboxylierung ist ein Vitamin K abhängiger
Vorgang wobei Vitamin K (der Cofaktor der ?-Carboxylierung) zu Vitamin
K Epoxid konvertiert wird, welches durch VKOR wieder zu Vitamin K
rezykliert werden muss. Während der ?-Carboxylierung werden in Vitamin
K abhängigen Proteinen wie Osteocalcin, Glutaminsäurereste zu gamma-
Carboxyglutaminsäure (Gla) umgewandelt. Diese posttranslationale
Modifikation ist für die biologische Aktivität verschiedener Proteine
essenziell. Osteocalcin wird von Osteoblasten gebildet und besitzt im
carboxylierten Zustand, die Fähigkeit Ca2+ in Knochen einzubauen.
Der -1639G>A Polymorphismus ist ein funktionaler SNP in VKORC1,
wobei das A Allel mit einer signifikanten Verminderung der
Promoteraktivität und einer 2-fach niedrigeren mRNA Expression
assoziiert ist, was für Leber Zellen dokumentiert ist. Diese Studie befasst
sich mit dem Einfluss des -1639G>A Polymorphismus auf die Expression
von VKORC1 in Osteoblasten. Um dies untersuchen zu können, wurden
Plasmide, die den VKORC1 Promoter mit entweder dem G oder dem A
Allel an der Position -1639 enthielten, in Osteoblasten transfiziert und die
Promoteraktivität mittels einem Dual Luciferase Reporter Gene Assay
ermittelt.
Es wurden zwei verschiedene Transfektionsmethoden verglichen –
Lipofetamine 2000 und Metafectene Pro, wobei nur die Transfektion mit
Metafectene zuverlässige Ergebnisse lieferte.
Die Ergebnisse des Reporter Gene Assays von Metafectene transfizierten
Zellen zeigten eine 43% höhere Promoter Aktivität für Promotoren die das
G Allel enthielten. Offensichtlich bedingt das A Allel, nicht nur in
Introduction
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Leberzellen sondern auch in Osteoblasten, eine verminderte
Promoteraktivität.
Um eine Verbindung zwischen dem Effekt des -1639G>A Polymorphismus
und Osteoporose herstellen zu können, wäre es notwendig zu zeigen,
dass derselbe Effekt auch dann noch zu beobachten ist, wenn der
VKORC1 Promoter das VKOR Gen selbst kontrolliert anstatt des
Luciferase Gens. Dafür würde man ein full length Konstrukt des VKORC1
Gens benötigen, doch der Versuch eines herzustellen schlug leider fehl.
Introduction
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III. INTRODUCTION
1. Vitamin K epoxide reductase complex subunit 1
    (VKORC1)
The activity of VKOR was first reported in 1970 by Bell R and Matschiner
J, but it took more than 30 years until it was possible to purify VKORC1.
Until 2004 several groups, Li et al. among them, tried to purify the VKOR
gene, but they were not successful. In 2004, Li et al. started a new attempt
to identify the VKOR gene on account of two reports of other research
groups: One study reported four markers for warfarin resistance on the
mouse chromosome 7 and on human chromosomes 10, 12 and 16 [Kohn
and Pelz, 2000]. The second study discovered a gene for combined
deficiencies of vitamin K dependent (VKD) proteins located on the human
chromosome 16p12-q21 [Fregin et al., 2002]. These findings prompted Li
and collegues to focus their search for the VKOR gene on chromosome
16. Out of 190 predicted coding sequences in the region 16p12-q21, 13
genes coding for integral membrane proteins could be identified and were
chosen for further analysis. Consequently, the VKOR gene could be
identified by specific inhibition of VKOR activity by a single siRNA pool.
At the same time, also in 2004, another group of researchers (Rost et al.
from the laboratory of J. Oldenburg) identified the VKORC1 gene
independently of Li et al. Rost, used genetic linkage analysis and
positional cloning based on sequence similarity between rats and humans
[Rost et al., 2004].
In 2004 both, the laboratory of Oldenburg and the laboratory of Stafford
were able to identify the VKORC1 gene.
Introduction
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1.1. Structure and Function of the VKORC1 gene
The VKORC1 gene (VKORC1; GenBank accession number AY587020) is
located on chromosome 16p 11.2, spans 5126 bp and consists of three
exons and two introns. A large family of homologues with significant
sequence similarities exists among plants, archaea, bacteria, vertebrates
and arthropods [Goodstadt et al. 2004].
The VKORC1 gene codes for a transmembrane protein, located in the
mammalian endoplasmatic reticulum [Cain et al. 1997] and consists of 163
amino acids [Li T. et al. 2004].  The protein is composed of three
transmembrane domains, the N-terminus is located in the lumen of the
endoplasmatic reticulum and the C- terminus is exposed to the cytoplasm
[Stafford DW 2005]. Goodstadt and Ponting [2004] found four cysteine
residues and one serine/threonine residue, which are absolutely
conserved (Cys 43, Cys 51, Cys 132, Cys 135, Ser/Thr 57). They are
considered to form the active site of VKORC1 as no other conserved polar
residues have been found.
                     Fig. 1. Proposed membrane topology of VKORC1
                                [Oldenburg et al. 2007: p. 3, figure 3]]
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VKOR is primarily expressed in the liver, kidney, heart and skeletal muscle
[Wang Y. et al 2005], and plays a central role in the important biological
process of ?-carboxylation. During ?-carboxylation glutamic acid residues
are carboxylated to ?-carboxyglutamate (Gla). ?-carboxylation is a vitamin
K depending process during which vitamin K hydroquinone, the cofactor
for ?-carboxylation, is converted to vitamin K epoxide. The latter form of
vitamin K is not active and has to be reduced to vitamin K hydrochinon
again. For the reduction VKOR is necessary [Wang et al 2006]. The
following Vitamin K-dependent proteins have to be ?-carboxylated: the
coagulation factors VII, IX, X, prothrombin, protein S, protein Z and protein
C, osteocalcin and matrix Gla-protein, proteins active in bone metabolism,
and Gas 6 (growth-arrest-specific protein 6) which is involved in cell
proliferation and apoptosis [Rost et al 2005].
1.2. Polymorphisms in VKORC1
In VKORC1 28 SNPs (single nucleotide polymorphisms) were identified by
Geisen et al. in 2005. The group found three silent SNPs in the coding
region of VKORC1, and 25 SNPs located in non-coding regions: 7 SNPs
in the promoter region, 11 in introns, and 5 in 5’UTR (untranslated region)
[Geisen et al. 2005].
Six of these SNPs form three main haplotypes (VKORC1*1, VKORC1*2,
VKORC1*3) which cover more than 99% of the genetic variability of the
VKORC1 gene in Europeans [Geisen et al. 2005]. The VKORC1*2
haplotype comprises the -1639G>A promoter polymorphism, which is the
functional SNP in VKOR, and is in perfect linkage disequilibrium (LD) with
the 1173C>T polymorphism in intron 1 of the VKORC1 gene [Geisen et al.
2005; Wang et al. 2008].
There are two main diseases caused by mutations in VKORC1: (i)
combined deficiency of vitamin K dependent coagulation factors type 2
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(VKCFD2) caused by a homozygous missense mutation in the VKORC1
gene, and (ii) the hereditary warfarin resistance as result of a
heterozygous missense mutation in VKORC1 [Geisen et al. 2005].
Warfarin is a widespread anticoagulant drug used for the prevention of
thromboembolic diseases for patients with mechanical heart valve
replacement, deep vein thrombosis and atrial fibrilation [Yuan et al. 2005].
Warfarin sensitivity and the dose requirement for warfarin is variable
between patients and differs between different ethnic populations. This
variability is associated with a polymorphism in the promoter region of the
VKORC1 gene at position -1639. Yuan et al [2005] found out that all
warfarin-sensitive patients were homozygous AA at the position -1639 and
had lowest dose requirements for warfarin. In contrast, patients who were
heterozygous AG or homozygous GG at the position -1639 required an
intermediate or high warfarin dose, respectively. By measuring the mRNA
expression, using a reporter gene assay, Yuan et al. [2005] detected a
44% higher VKORC1 promoter activity for the -1639 GG genotype
compared to the -1639 AA genotype.
             Fig. 2: Promoter activity of the plasmids pGL3-A, pGL3-G and pGL3-basic
                        [Yuan et al. 2005: p.1749, figure 2]
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The VKORC1*2 haplotype with the -1639A allele also explains the
differences in warfarin requirement between ethnic populations. Chinese
and Malay require lower warfarin dose than Europeans and Indians and in
Blacks the overall mean warfarin dose is higher compared to Whites
[Wang et al. 2008]. Wang et al [2008] showed that the mean warfarin dose
is identical in these two ethnic groups when they are grouped by the
-1639G>A and 1173C>T genotype, so the greater overall mean in Blacks
is a result of the lower frequency of the minor -1639 A and 1173 T alleles
which require reduced dosing of warfarin.
2. Promoters
Transcription involves synthesis of an RNA chain, which is identical to the
coding strand and complementary to the template strand of a DNA duplex.
Synthesis of RNA is catalyzed by the enzyme RNA polymerase.
Transcription starts when the RNA polymerase binds to the promoter,
which contains the start point. From this start point, RNA polymerase
moves along the DNA molecule synthesizing RNA in 5’?3’ direction.
Transcription ends when the RNA polymerase reaches a terminator
sequence.
2.1. Bacterial promoters
The sequence of a large part of the promoter is not important, but there
are some short stretches within the promoter which are conserved and
which are very important for its function as a binding site for RNA
polymerases as well as other proteins. In bacterial promoters there are
four (sometimes five) conserved features: the start point, the -10
sequence, the -35 sequence and the separation between the -10
sequence and the -35 sequence [Knippers R., 2006].
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· The startpoint:
is usually a purine (very often the central base of an CAT triplet).
· The -10 sequence:
is a 6 bp region directly upstream of the startpoint. The center of the
hexamer generally is close to 10 bp upstream of the start point and
the consensus of this -10 sequence is TATAAT.
· The -35 sequence:
is also a conserved hexamer with the center close to -35 bp
upstream of the startpoint and the consensus is TTGACA.
· The distance separating -10 and -35:
in 90% of the promoters the distance between the -10 sequence
and the -35 sequence is 16 – 18 bp. It is not important what
sequence the actual intervening region is, but holding the
appropriate distance between the two sites is critical for the
geometry of the RNA polymerase.
· The UP element:
The UP element is an AT rich sequence further upstream, which is
typically found in highly expressed promoters. Its function is to
interact with the a - subunit of the RNA polymerase [Knippers R.,
2006] .
2.2. Eukaryotic promoters
Like bacterial promoters, eukaryotic promoters also contain conserved
sequences which are essential to the function of the promoters as a
binding site of RNA polymerases. There are four such elements: (i) the
initiator element, (ii) the TATA – box, (iii) the downstream promoter
element (DPE) and (iv) the CpG islands. In contrast to bacterial promoters,
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eukaryotic promoter elements are not as highly conserved as bacterial
ones and the promoters do not necessarily comprise all of the promoter
elements [Knippers R., 2006] .
· The initiator element:
is a pyrimidin-rich sequence containing the start point of eukaryotic
transcription which is a purine, usually an adenine.
· The TATA-box:
The  TATA-box  is  an  AT  rich  stretch  of  conserved  DNA.  Its
consensus is TATAAA and it is located in the region between -26
bp and -34 bp upstream of the startpoint. This TATA box is similar
to the -10 sequence in bacterial promoters. It is rarely found in
promoters of housekeeping genes but very frequent in genes which
are regulated.
· The downstream promoter element:
The DPE is located in the range of +28 bp to + 32 bp downstream
of the startpoint. Its sequence is not highly conserved as it is in the
case of the initiator sequence. Its consensus is A/T. G. A/T. C/T.
G/A/C.
· The CpG islands:
Most of the promoters of housekeeping genes are characterized by
stretches of consecutive GC basepairs including CpG islands. CpG
islands are special CG elements with the consensus of GGGCGG
[Knippers R., 2006].
2.3. The promoter variant -1639G>A of the VKORC1 gene
Promoter polymorphisms are usually point mutations within the promoter
sequence. The sequence change may alter binding sites for proteins that
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are necessary for the expression of the gene. As a result, the expression
of the gene increases or decreases [Murken et al. 2006].
This seems to apply also to the -1639G>A polymorphism in VKORC1.
Wang et al [2008] showed that the -1639G>A promoter polymorphism is a
functional SNP in VKORC1. This polymorphism is located in the second
nucleotide of an E-box with the consensus sequence CA/GNNTG. The
SNP changes the second base of the E-box from A to G, which abolishes
the E-box consensus sequence and leads to changes of the VKORC1
promoter activity [Yuan et al. 2005].
The A allele of this -1639 SNP is associated with a significant decrease of
the VKORC1 promoter activity and therefore with a lower VKORC1 mRNA
expression [Geisen et al. 2005]. Wang et al. [2008] confirmed the earlier
data indicating that the A allele of this polymorphism decreases promoter
activity. They used HepG2 cells (liver cells) and measured the mRNA
expression using a reporter gene assay. Like the group around Geisen
[2005] they too found that the -1639A allele is associated with a 2-fold
lower mRNA expression compared to the -1639G allele, but this decrease
of promoter activity is limited to HepG2 cells and could not be observed in
other tissues like B-lymphocytes or heart tissue.
3. Bone
3.1. Bone physiology
Bone tissue consists of bone cells, bone matrix, and mineral salts. The
bone matrix represents the organic part of bone and includes collagen
fibers which are important for the flexibility of bone. Mineral salts, such as
hydroxyapatite [Ca10(PO4)6(OH)2] and calcium phosphate
[Ca8H2(PO4)6(H2O)5], form the anorganic part of bone and make up about
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2/3 of the bone weight. These mineral salts are incorporated between the
collagenous molecules and guarantee hardness and firmness of the bone
[Seibl MJ et al. 2006; Bilezikian JP et al. 2002]
Our skeleton is formed of more than 200 bones which have three
important functions: (i) They support posture and motion of the human
body and (ii) protect the inner organs, the central nervous system and
bone marrow. To be able to fulfil these two tasks, bone has to be hard,
flexible and light at the same time. (iii) Third, bone is the biggest calcium
reservoir in the human body and about 99% of the calcium is stored in
bone [Seibl MJ et al. 2006; Bilezikian JP et al. 2002].
There are two types of bone tissue: spongy (trabecular) bone which is
composed of little beams, and compact (cortical) bone which is very
dense. Both bone types are solid mineralized matrices with small canals
(canaliculi), spaces (lacunae), and bone cells. In trabecular bone, the
matrix, lacunae and bone cells are organized in the form of thin
interconnecting spicules, whereas cortical bone is organized in Haversian
systems or osteons, consisting of a canal containing a blood vessel
surrounded by concentric and interstitial lamellae [Seibl MJ et al. 2006;
Bilezikian JP et al. 2002].
3.2. Bone formation
Bone consists of the organic matrix, water and different types of bone cells
which are osteoblasts, osteoclasts, lining cells and osteocytes.
Osteoblasts synthesize and mineralize the collagenous extracellular matrix
of bone. Bone is a dynamic tissue that is remodelled continuously
throughout life to renew the skeleton and to maintain its structural and
anatomical function. Bone remodelling is characterized by constant
resorption and formation of bone and it is essential for adapting bone to
changing mechanical strain of the skeleton. This process of bone
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formation is performed by osteoclasts that remove old bone, and
osteoblasts that subsequently form new bone [Manolagas et al. 1995].
       Fig. 3: Schematic illustration of the bone remodelling process
                  CFU-GM – hematopoetic progenitor cell, CFU-GM – mesenchymal progenitor cell
                  [Manolagas et al. 1995: p.306, figure 1]
Normally, bone remodeling proceeds in cycles. The removal and
resorption of old bone is initiated by osteoclasts which lyse small areas of
bone by acidification and proteolytic digestion. After resorption of the
bone, the osteoclasts leave the resorption site and osteoblasts invade to
form new bone by secreting a matrix of collagen and other proteins, called
osteoid, which is eventually mineralized. Finally, the surface of the new
bone is covered by lining cells [Manolagas et al. 1995].
Osteoblasts as well as osteoclasts originate in the bone marrow, but the
marrow progenitors of both cells differ. Osteoclasts derive from the
hematopoetic linage, while osteoblasts derive from pluripotent
mesenchymal stem cells of the bone marrow [Manolagas et al. 1995,
Koshihara et al. 2003].
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3.3. Osteoblasts
Pluripotent mesenchymal stem cells as well as hematopoetic stem cells
originate in the bone marrow and cooperate through direct cell-to-cell
interaction and release of cytokines and growth factors. The progenitor
cells of osteoblasts, called fibroblast colony-forming units (CFU), form
adherent colonies of stromal cells in marrow cell-cultures, which can
become osteoblasts as well as chondrocytes, adipocytes, fibroblasts and
muscle cells [Manolagas et al. 1995].
Osteoblasts play an essential role in bone formation and bone remodelling
since they synthesize and mineralize the collagenous extracellular matrix
of bone. In the beginning of bone formation the new bone is not
mineralized yet. Only after deposition of hydroxyapatite, the new bone
reaches the mechanical firmness that is needed to fulfil its anatomical and
structural function [Pietschmann et al. 1999].
Osteoblasts are also important for the development of osteoclasts as their
differentiation of hematopoetic precursers can only be accomplished in the
presence of stromal-osteoblastic cells, which mediate the effects of
systemic hormones like parathyroid hormone and 1,25-dihydroxyvitamin
D3, and locally produced factors, such as interkeulin-6 and interleukin-7,
which stimulate the development of osteoclasts [Manolagas et al. 1995].
3.4. Osteocalcin
Osteocalcin, a low-molecular-weight protein of 49-50 amino acids [Binkley
et al. 1995], is produced in osteoblasts during bone matrix formation and
accounts for 15-20% of the non-collagen proteins in the bone matrix.
It comprises two domains: the Gla domain and the C-terminal domain. In
the Gla domain there are three glutamyl (Glu) residues at the positions 17,
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21 and 24, which can be post-translationally modified to ?-carboxyglutamyl
(Gla) residues in a ?-carboxylation process [Pearson A. 2007]. These Gla
residues have a highly specific affinity to the calcium ion of the
hydroxyapatite molecule [Price 1989], and they are able to bind Ca2+ ions.
Promoting a protein - Ca2+- phospholipid interaction through binding Ca2+
ions is essential for the biological activity of osteocalcin [Esmon et al.
1975]. Because of the ability to bind calcium in bone, the concentration of
osteocalcin in bone is directly proportional to the amount of calcium
[Hauschka and Reid 1978, Lian et al. 1982]. Not all newly synthesized
osteocalcin is incorporated into bone, a small amount of osteocalcin is
passed into the circulation where it can be measured and used as a
marker for bone formation [Delmas et al. 1985].
The C-terminal domain of osteocalcin is important for chemotaxis for
osteoclast-like cells [Glowacki et al. 1991, Liggett et al. 1994], because of
the ability of this domain to build up a concentration gradient [Vermeer et
al. 1996].
Synthesis and posttranslational modification of osteocalcin are dependent
on vitamin D and vitamin K. The dependence on vitamin D is due to a
vitamin D-responsive element in the promoter of osteocalcin, which is able
to stimulate the synthesis of osteocalcin directly [Lian et al. 1989], Vitamin
K is important because of its function as a cofactor in the posttranslational
?-carboxylation of the three glutamic acids residues in preosteocalcin.
4. Osteoporosis
Osteoporosis is a multifactorial disorder of bone. It is characterized by a
reduced bone mass and bone mineral density (BMD) with an increased
fragility of the bone and as a result an increased risk of fractures. The
World Health Organisation (WHO) criteria for the diagnosis of
osteoporosis are based on comparison with peak adult bone mass
measured by bone densitometry. According to these criteria, osteoporosis
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is characterized by a bone mineral density of more than 2.5 standard
deviations (SD) below the mean value of peak bone mass in young
healthy individuals. A moderate decrease of BMD in the range of at least 1
SD to no more than 2.5 SD below the mean value of the peak bone mass
is called osteopenia [Weber P. 2001].
                                          Fig. 4: Distribution of bone mineral density in healthy women aged
                                                     between 30-40 years. [Kanis JA; 2002]
The loss of bone mass is a result of an imbalance between bone formation
and bone resorption. In healthy bone, bone remodeling is necessary to
maintain bone strength and to be able to react on changing mechanical
strain. An imbalance of bone resorption and bone formation can be
responsible for excessive removal of bone and too little bone formation
which leads to reduced bone mass [Pietschmann and Peterlik 1999].
Such reduced bone mass usually concerns both cortical and trabecular
bone, but not necessarily to an equal extent. The effects on cortical bone
are thinning of the cortex [Peacock et al. 1998, Atkinson PJ 1965] and
increased intracortical porosity [Atkinson PJ 1965, Bousson et al. 2001],
whereas the effects in trabecular bone refer to trabecular thinning
[Atkinson PJ 1967, Aaron et al. 1987] and loss of trabecular connectivity
[Aaron et al. 2000, Dempster DM 2000].
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Two main forms of osteoporosis can be distinguished: (i) primary
osteoporosis, including the postmenopausal and the senile osteoporosis,
and (ii) secondary osteoporosis - this form is caused by other diseases like
diabetes mellitus, diseases of the liver, immobilization, malabsorption,
chronic treatment with glucocorticoids, therapy with anticoagulants, and
alcohol abuse [Pietschmann et al. 1999].
Postmenopausal osteoporosis:
The major pathophysologic factor for the development of the
postmenopausal osteoporosis is estrogen deficiency in women after the
menopause. An important determinant thereby is the severity of the
estrogen deficiency. Several studies proved that a lack of estrogen leads
to increased bone resorption, since estrogen inhibits osteoclastogenesis
[Schiller et al. 1997], reduces the resorption activity of osteoclasts [Pacifici
et al. 1991] and inhibits the production of different cytokines which improve
bone resorption [Pietschmann et al 1999]. Therefore, postmenopausal
bone loss is associated with excessive osteoclast activity. The bone loss
occurs primarily in trabecular bone [Manolagas et al. 1995].
There are also other factors that play a role in postmenopausal
osteoporosis, such as the peak bone mass which is the maximum bone
density at the end of the development of the skeleton, the extent of
physical exercise, environmental influences, and genetic determinants.
Senile osteoporosis:
Senile osteoporosis develops after 70 to 75 years of life. The main
determinant of this type of osteoporosis is a vitamin D deficiency which is
common among elderly people, because of reduced exposure to the sun
light, imbalanced diet and reduced kidney-activity, especially among
patients living in nursing homes. This lack of vitamin D leads to a decrease
of serum calcium which is compensated by an increased secretion of
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parathyroid hormone. This can keep the serum calcium in the normal
range, but still results in increased bone resorption. The bone loss of
senile osteoporosis affects mainly cortical bone [Manolagas et al. 1995].
Another reason for bone loss in aging is the fact that in each remodeling
cycle the amount of formed bone decreases with age, because there are
not enough osteoblasts available in proportion to the demand for them,
and the demand for osteoblasts is determined by the frequency of new
cycles of bone remodeling [Manolagas et al. 1995].
4.1. Environmental factors for osteoporosis
As mentioned above, osteoporosis is a multifactorial disease with several
risk factors including genetic factors, environmental factors such as
smoking, alcohol abuse, low calcium intake, delayed menarche, low body
weight, and physical inactivity.
Adverse risk factors                                  Protective factors
Smoking                                                      High phytoestrogen intake
Alcoholism                                                  Sports activity
Low calcium intake                                     Pregnancy
Vitamin D insufficiency
Low body weight
- BMI <18-20 kg/m2
Estrogen deficiency
- Delayed menarche
- Early menopause
- Bilateral ovariectomy
- Premenopausal amenorrhea
High parathyroid hormone
History of fracture
- Personal and in first-degree
relative
Caucasian race
Advanced age
Female
Dementia
Table 1. Clinical risk factors for osteoporosis [Kung AWC and Huan QY; 2007]
A study of Cornuz et al. [1999], which was running over 12 years and
included 116,229 female nurses aged 34-59 at the beginning of the study,
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showed that smokers are more likely to have hip fractures than non-
smokers. Ten years after stopping of smoking the hip fracture risk
decreased. Liu et al. [2003] demonstrated that cigarette smoke extract
inhibits the in vitro differentiation of human osteoprogenitor cells into
osteoblast-like cells. As a result previous smokers have no increased bone
resorption but a lower bone mineral density (BMD) than people who never
smoked, because less osteoblast-like cells mean less osteoblasts and
therefore less bone formation. This decreased bone formation leads to a
lower BMD although bone resorption is on a normal level.
Alcohol also reduces BMD as well as markers of bone turnover and levels
of parathyroid hormone, which leads to the suggestion that alcohol may
reduce bone remodeling [Rapuri et al. 2000]. A larger study of Hoidrup et
al [1999] showed an increased risk of hip fractures depending on the
extent of increased alcohol consumption.
Also, inadequate dietary calcium and/or vitamin D levels have negative
effects on bone remodeling and BMD, because impaired calcium
absorption with a compensatory increase of parathyroid hormone (PTH)
levels leads to increased bone resorption [Reginster JY, 2005]. In contrast,
BMD and serum 25(OH)D3 increase significantly in case of vitamin D and
calcium supplementation, whereas serum parathyroid hormone and risk of
hip fractures decrease [Freskanich et al., 2003; Grados et al 2003].
Low body weigth (<44kg) was associated with risk of having low BMD at
the spine and hip; delayed puberty, characterized with an onset of
menstruation beyond 14 years, was also associated with a higher risk for
low BMD at the hip. This was also observed for physical inactivity [Kung
and Huang 2007].
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4.2. Genetic factors for osteoporosis
Despite the key role of environmental factors in osteoporosis, genetic
factors seem to have an influence on the development of osteoporosis.
Twin- and family studies indicate that 60-85% of the variance in bone
mineral density is genetically determined [Krall& Dawson-Hughes 1993;
Gueguen et al. 1995]. It is well established that BMD which is widely used
as a criterion for the diagnosis of osteoporosis is under genetic control,:
It seems likely that genes which influence BMD are also involved in the
development of osteoporosis. However, it is unlikely that there are only
few genes with a major influence on BMD. The genetic component of
osteoporosis is determined by an assembly of multiple genes, each with a
small individual effect. Most likely, each gene is only responsible for less
than 5% of the genetic variance in the general population [Kung and
Huang 2007].
                      Fig. 5. Common model of susceptibility to osteoporosis and fracture
                                                          [Kung AWC and Huang QY, 2007]
Several candidate-gene association studies have been performed. Such
studies are powerful instruments for the identification of genes with small
effects. By the end of 2005, 63 genes had been associated with BMD and
osteoporosis-related phenotypes [Kung and Huang 2007].
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Initially, linkage studies were used to identify genes with an effect on BMD:
The advantage of linkage studies is their ability to identify both novel
genes or pathways and genes with larger phenotypic effects. More than 10
genome-wide linkage scans in humans have been performed and have
identified some significant or suggestive linkage regions for BMD [Munafo
et al. 2004; Ioannidis et al. 2002; Ioannidis et al. 2004; Efstathiadou et al.
2001; Mann et al. 2001; Gong et al. 1999; Thakkinstian et al. 2004]. A
recent meta-analysis of genome-wide linkage scans in osteoporosis
revealed that regions on chromosomes 1p, 3p, 6, 10, 16p, 18, 20p and
22q were associated, the region 16p had the strongest association [Lee et
al. 2006]
The first gene associated with osteoporosis, was the bone morphogenetic
protein 2 gene (BMP2). It was identified by linkage scans in humans.
BMP2 is an important regulator of osteoblast differentiation and there are
indications that it is significantly associated with osteoporosis risk and
BMD [Styrkarsdottir et al. 2003].
4.3. Biochemical markers of bone turnover and fracture
       risk
The importance of estrogen deficiency in the rapid bone loss around the
time of menopause has been recognized for several years [Albright et al.
1941; Lindsay et al. 1980], but circulation estradiol levels explain only a
small proportion of the interindividual variance of bone mineral density
(BMD) and bone loss [Slemenda et al. 1996]. Measuring areal bone
mineral density (aBMD) can predict fractures [Johnell et al. 2005; Stewart
et al. 2006], but there is also evidence, that measuring bone metabolism
by means of biochemical markers of bone turnover can predict fractures
independently of bone mass [Gerdhem et al. 2004; Garnero et al. 1996;
Garnero et al. 2000; van Daele et al. 1996]. Markers of bone turnover are
biochemical substances in blood and urine that are produced or released
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during bone turnover. There are two categories: (i) enzymes or other
proteins secreted by osteoblasts or osteoclasts and (ii) substances which
are produced during the formation or breakdown of type I collagen, which
is the primary protein forming the organic matrix of bone [Looker et al.
2000].
Markers of bone formation:
· Osteocalcin (OC)
· Bone-specific alkaline phosphatase (BAP)
· C-terminal propeptide of type I collagen (PICP)
· Intact N-terminal propeptide of type I collagen (PINP)
· Bone specific alkaline phosphatase (ALP)
Markers of bone resorption:
· Type I collagen N-telopeptides (NTX)
· Type I collagen C-telopeptide (CTX)
· TRACP isoform 5b (TRACP5b)
· Deoxypyridioline (DPD)
Several studies indicate that bone markers are associated with fracture
risk. Szulc et al. [1996] showed that total osteocalcin, carboxylated and
undercarboxylated osteocalcin (OC) and alkaline phosphatase (ALP) were
significantly higher in hip fracture cases than in controls. Other than total
OC, cOC and ALP, serum ucOC remained an independent predictor of hip
fracture risk when age was included in the model of regression. The age-
adjusted odds ratio for hip fracture was three times higher in women with
increased undercarboxylated osteocalcin (ucOC) at baseline. Garnero et
al. [2000] showed that increased levels of some biochemical markers of
bone turnover, including BAP, serum OC, PICP and PINP, are associated
with increased risk of hip fractures although only BAP was significant.
Moreover, Garnero et al. [1999] were able to show that there is a
significantly greater rate of bone loss in postmenopausal women when
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these bone formation markers are increased. Thus, it was reported that
serum osteocalcin is associated with hip bone loss in elderly women and
in perimenopausal women [Chapurlat et al. 2000; Bauer et al. 1999;
Dresner-Pollak et al. 1996; Iki et al. 2006]. Lenora et al. [2007] were also
able to demonstrate that there is a significant association of serum OC,
urinary OC and to some extent serum TRACP5b with bone density loss in
hip. Gerdhem et al. [2004] reported a predictive feature of serum
TRACP5b and urinary OC for forthcoming (vertebral) fractures.
4.4. Vitamin K
Vitamin K is naturally found in two forms. The primary dietary source of
vitamin K is vitamin K1 (phyllochinone) which is found in high
concentrations in leafy, green vegetables and in some oil plants. Vitamin
K2 (menaquinones) is found in animal meats, dairy products and
fermented foods (Kalkworf et al. 2004). Vitamin K is a fat-soluble protein
and its intestinal absorbtion is dependent on bile-salts that are
components of the micelles. These micelles incorporate vitamin K in the
small intestine where it is taken up by the intestinal mucosa from which the
vitamin is then set free to the lymphatic system and to the circulation
[Vermeer et al. 1996].
Hodges et al. [1991,1993] and Feskanich et al. [1999] were able to show
that vitamin K has beneficial effects on bone health, and Kameda et al.
[1996] proved that Vitamin K2 affects osteoclasts directly and as a result
inhibits bone resorption.
Studies of Koshihara et al. [1996], Koshihara and Hoshi [1997], and
Miyake et al. [2001] showed that the inhibition of osteoclastic bone
resorption and the stimulation of osteoblastic bone formation relates to
MK-4 (menaquinone-4) and is observed in different assay systems and
different species. Moreover, Koshihara et al. [2003] could confirm the
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suggestion that there is a predominant effect of Vitamin K2 on bone
formation via osteoblasts, by showing that both types of vitamin K promote
the differentiation of bone marrow mesenchymal progenitor cells to
osteoprogenitor cells and also inhibit the formation of osteoclasts in
human bone marrow culture.
4.5. The vitamin K cycle
The vitamin K-dependent ?-carboxylation system is a multicomponent
system of proteins in the endoplasmatic reticulum. The system post-
translationally modifies vitamin K-dependent proteins such as the
coagulation factors VII, IX, X, prothombin, protein S, protein Z, protein C,
and the bone related proteins osteocalcin and matrix Gla protein [Stafford
2005]. During the post-translational modification glutamic (Glu) acid
residues of the proteins are converted to ?-carboxyglutamic (Gla) residues
which are then able to bind calcium. The above mentioned proteins are
only biologically active following gamma-carboxylation [Wallin et al. 2003].
The system consists of the vitamin K-dependent ?-carboxylase and the
enzyme vitamin K 2,3-epoxide reductase (VKOR – see 1.1. above). The
former requires the reduced hydrochinone form of vitamin K as its
cofactor, while the latter produces the cofactor [Wallin et al. 2003].
Because of  this role of  VKOR in the vitamin K cycle,  mutations in VKOR
could have an impact on the proper function of this cycle.
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Fig. 6. The vitamin K cycle
            Mediated by the enzyme gamma glutamyl carboxylase Glu residues are converted into Gla
            residues. Thereby vitamin K hydrochinone is turned into vitamin K epoxide, which has to be
            reconverted to be reusable. In a first step vitamin K epoxide is turned into vitamin K quinone
            in a reaction catalyzed by the enzyme vitamin K epoxide reductase (VKOR). In a second
            step vitamin K hydrochinone is regenerated and is then functional again. The regeneration
            can be inhibited for example by Warfarin [Bell et al., 1972].
            (downloaded from http://www.inchem.org/documents/ehc/ehc/ehc175.htm)
4.6. g-carboxylation
Gamma-carboxylation requires the abstraction of a proton from the 4th
carbon of glutamate by reduced vitamin K. This reaction is catalysed by
the vitamin K gamma glutamyl carboxylase (GGCX), while CO2, O2 and
the reduced form of vitamin K are co-substrates. Through this reaction, for
each carboxylated glutamate a molecule of vitamin K epoxide is formed.
The generated vitamin K epoxide is converted back to reduced vitamin K
by Vitamin K epoxide reductase (VKOR). On account of this ability of
VKOR, vitamin K can be reused for several cycles of
g-carboxylation.
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4.7. Vitamin K and osteoporosis
As mentioned above, Vitamin K is essential for the ?-carboxylation of
osteocalcin which binds calcium ions of hydroxyapatite when
carboxylated.
Vitamin K deficiency leads to elevated concentrations of
undercarboxylated osteocalcin (ucOC) or a low ratio of serum
carboxylated OC (cOC) to serum total OC. The deficiency seems to be
common in postmenopausal women [Knapen et al. 1989, Plantalech et al.
1990], and contributes to development of osteoporosis and the increased
risk of hip fracture in elderly [Iwamoto et al. 2006]. This was confirmed by
several studies associating a high serum concentration of ucOC or low
serum concentrations of carboxylated osteocalcin with skeletal turnover
[Knapen et al. 1993], low bone mineral density [Szulc et al. 1994], and
increased risk of osteoporotic fracture [Szulc et al. 1993; Szulc et al. 1996;
Vergnaud et al. 1997; Luukinen et al. 2000]. Clinical use of vitamin K
antagonists, like oral anticoagulants (coumarin derivatives), also leads to
low bone mineral density [Fiore et al. 1990; Philip et al. 1995; Resch et al.
1991; Sato et al. 1997; Caraballo et al. 1999] and increased fracture risk
[Caraballo et al. 1999].
Vitamin K seems to have a positive effect on bone metabolism as vitamin
K supplementation increases serum phylloquinone concentration and
reduces ucOC [Binkley et al. 2000]. Miki et al. [2003] and Ozuru et al.
[2002] came to similar results when they demonstrated that vitamin K
rapidly decreases the ucOC level and increases the cOC level.
5. Focus of the study
This study focuses on the examination of the influence of the -1639G>A
promoter polymorphism on the expression of VKORC1 in osteoblasts and
Introduction
27
addresses the question of whether there are any effects of this
polymorphism on bone.
Until now, there have been no investigations on the effect of
polymorphisms of the VKORC1 gene on ?-carboxylation of osteocalcin. By
testing the influence of the -1639G>A polymorphism of the VKORC1 gene
in osteoblasts I hoped to be able to establish a connection between this
mutation and osteoporosis.
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II. MATERIALS AND METHODS
1. Materials
1.1. Reagents
Agarose
(Sigma Aldrich, Germany)
AmpliTag Gold®  with GeneAmp® 10x PCR Buffer II
(Roche, USA)
Aqua bidestillata
(Mayrhofer Pharmazeutika, Austria)
Bacteriological Agar
(Sigma Aldrich, Germany)
Big Dye® Terminator v3.1 Cycle Sequencing Kit with Big Dye® Terminator
v3.1, Sequencing Buffer (5x) and Big Dye® Terminator Mix
(Applied Bioscience, UK)
CriterionTM Precast Gel, 5% Acrylamid Precast Gel
(Bio-Rad Laboratories, USA)
Dimethyl Sulphoxide (DMSO)
Sigma Aldrich, Germany
D-MEM/F-12 (1x) liquid 1:1
Invitrogen
DMEM+GlutaMax™-I 1x
(Gibco, UK)
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Dual- Luciferase® Reporter Assay System
(Promega Corporation, USA)
Ethanol 96% for analysis
(Merck, Darmstadt, Germany)
Ethidium bromide (10mg/ml)
(Sigma Aldrich, Germany)
FastRulerTMDNA Ladder, High Range
(Fermentas International, Canada))
Fetal Bovine Serum (FBS)
(Gibco, UK)
Gel Star
(Invitrogen, USA)
GeneRuler™ 100bp Ladder
(Fermentas International, Canada)
Gentamicin  50mg/ml
(Gibco, Paisly, UK)
Glycerol, 99,5%+% A.C.S. Reagent
(Sigma Aldrich, Germany)
LB Broth
(Becton Dickinson, USA)
Lipofectamine™ 2000 Reagent
(Invitrogen, USA)
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Loading Buffer (5x)
(Elchrom Scientific AG, Switzerland)
MgCl2 Solution 25mM
(Roche, USA)
Metafectene™PRO
(Biontex, Germany)
Montage™ SEQ96 Sequencing Reaction Cleanup Kit
(Millipore, USA)
OptiMEM® I- + GlutaMax™-I 1x
(Gibco, UK)
pBR322 DNA-Msp I Digest
(New England BioLabs, USA)
PBS
(Gibco, UK)
PfuUltra™ Hotstart DNA Polymerase, PfuUltra™ HF Reaction Buffer (10x)
(Stratagene, USA)
QIAprep® Spin Miniprep Kit, EndoFree® Plasmid Maxi Kit
(Qiagen Inc., USA)
Rapid- Load™ PCR Loading Dye
(OriGene Technologies, USA)
Restriction enzymes Hind III (10U/µl), Xho I (10U/µl), Xba I (10U/µl)
(Fermentas International, Canada)
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S.O.C. Medium
(Invitrogen, USA)
T4 DNA Ligase (5U/µl) with Ligation buffer (10x)
(Roche Diagnostics, Germany)
5x TBE Buffer
(Eppendorf, Germany)
0.05% Trypsin- EDTA 1x
(Gibco, UK)
1.2. Cells:
DH5? cells
Osteoblasts
ATCC®, Nr.: CRL-11372
1.3. Vectors for cloning:
pGL3 basic vector
Promega Corporation, Madison, WI, USA
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Base pairs 4818 bases
Promoter (none)
Enhancer (none)
Multiple cloning site 1-58
Luciferase gene (luc+) 88-1740
Glprimer2 biding site 89-111
SV40 late poly(A) signal 1772-1993
Rvprimer4 biding site 2061-2080
CoIE1-derived plasmid replication origin 2318
Beta-lactamase gene (Ampr) 3080-3940
F1 origin 4072-4527
Synthetic (upstream) poly(A) signal 4658-4811
Rvprimer3 binding site 4760-4779
pGL3-G and pGL3-A:
Plasmids composed of the pGL3 vector with and VKORC1 promoter
sequences corresponding to the
-1639G allele and -1639A allele, respectively, had been produced by a
fellow student and were at my disposal.
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phRL-TK vector
Base pairs 4045
HSV-TK promoter 7-759
Chimeric intron 826-962
T7 RNA polymerase promoter (-17 to +2) 1006-1024
T7 promoter transcription start site 1023
hRluc reporter gene 1034-1969
SV40 late poly(A) region 1991-2212
Beta-lactamase (Ampr) coding region 2359-3219
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2. Methods
2.1. Production of the plasmids pGL3-G and pGL3-A
The pGL3-G and pGL3-A plasmids, containing the promoter sequence of
VKORC1 variant G or A , had been generated previously and were stored
in glycerol at -80°C. To produce fresh plasmid, a small aliquot of the
glycerol stock was obtained with a sterile pipette tip, distributed on a LB
agar plate containing 50 µg/ml ampicillin and incubated over night at 37°C.
Plasmid DNA was isolated from the bacteria with either the QIAgen Spin
Miniprep Kit. or the EndoFree Plasmid Maxiprep Kit for the transfection of
cells (osteoblasts). The concentration and quality (optical density = ratio of
260nm/280nm) of the DNA was measured with a NanoDrop® ND- 1000
Spectrophotometer.
2.2. Miniprep
The QIAgen Spin Miniprep Kit contains following reagents: Buffer P1 +
RNase A, Buffer P2, Buffer N3, Buffer PE + ethanol, Buffer EB, Collection
tubes and QIAprep Spin Columns.
Single bacterial colonies were picked, inoculated in 2ml LB-medium
containing 100 µg/ml ampicillin and incubated with shaking at 37°C. After
16 hours, 1.5 ml of the culture were transferred into a 1.5ml tube
(Eppendorf) and centrifuged at 10000 rpm for 5 min. The supernatant was
discarded and the pelleted bacterial cells were resuspended in 250µl
Buffer P1. 250µl Buffer P2 was added to lyse the cells and to denature
chromosomal and plasmid DNAs as well as proteins. By adding 350 µl
Buffer N3 the lysate was neutralized and adjusted to the high-salt binding
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conditions, which causes precipitation of denatured proteins, chromosomal
DNA and cell debris, while the plasmid DNA renatured and stayed in
solution. The solution was centrifuged at 13000 rpm for 10 min at room
temperature and the supernatant containing the plasmid DNA was applied
to the QIAprep spin column and again centrifuged for 1 min at 13000 rpm.
The plasmid DNA bound to the QIAprep silica membrane, the flow-through
was discarded. To remove endonucleases and salts, the spin column was
washed with 500µl Buffer PB and 750µl Buffer PE, the flow-through was
discarded and the spin column was centrifuged for an additional 1 min at
13000 rpm to remove residual wash buffer. Then the plasmid DNA was
eluted with 50µl ddH2O by incubating at room temperature and
centrifuging.
To examine the size and the amount of the eluted plasmids, the plasmids
were applied on a 0.8% agarose gel (0.32 g agarose and 40 ml of 1x
TBE).
Running conditions for agarose gels were generally 100V, 50 min, at room
temperature.
2.3. Restriction digestion
To test, whether the plasmids still contained the right insert after the long
storage period at –80°C, the plasmid DNA was digested with the
restriction enzymes HindIII and XhoI. The mastermix for each sample
contained 2µl 10x Puffer (R), 1µl HindIII, 1µl XhoI, 11µl ddH2O and 5µl
plasmid DNA. The final reaction volume was 20µl. Then the reaction mix
was incubated for 2 hours at 37°C and afterwards the plasmid DNA was
again examined on an 0.8% agarose gel.
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2.4. Maxiprep
For the large prep 100µl bacterial culture were inoculated in 4 ml LB-
medium containing 100 µg/ml ampicillin and incubated on a shaker at
37°C for 16 hours. From this culture 100 µl were inoculated in 100 ml LB-
medium in an Erlenmeyerkolben and incubated on a shaker at 37°C at
125 rpm. After 16- 18 hours the bacterial culture was pelleted at 6000 x g
for 15 min at 4°C and the supernatant was discarded. The pellet was
resuspended to homogeneity in 10 ml Buffer P1, 10 ml Puffer P2 was
added and incubated at room temperature for 5 min. Then 10 ml Buffer P3
was added, the lysate was poured into the barrel of the QIAfilter cartridge,
incubated at room temperature for 10 min and then filtered through the
cartridge into a 50 ml tube. Buffer ER (2.5 ml) was added to the filtered
lysate and incubated on ice for 30 min. A QIAGEN- tip 500 was
equilibrated by applying 10 ml Buffer QBT and the column was allowed to
empty by gravity flow. The filtered lysate was applied to the QIAGEN- tip
and allowed to enter the resin by gravity-flow. Afterwards the QIAGEN- tip
was washed two times with 30 ml Buffer QC, then DNA was eluted with 15
ml Buffer QN. The DNA was precipitated by adding 10.5ml isopropanol at
room-temperature, following centrifugation at 15000 x g for 30 min at 4°C.
The supernatant was removed carefully and discarded. The DNA pellet
was washed with 5ml endotoxin-free 70% ethanol, centrifuged at 15000 x
g for 10 min and the supernatant was discarded again. At last, the pellet
was air-dryed for 5- 10 min and redissolved in 100 µl of 1 x TE.
The DNA was quality controlled on a 0.8% agarose gel, aliquoted and
stored at –20°C.
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Glycerol stock
Fresh glycerol stocks were prepared for long time storage. 600µl of the
bacterial culture and 300µl glyerol were homogeneously mixed and stored
at -80°C.
2.5. Sequencing
To ensure, that the plasmids contained the right insert with the right
sequence of the promoter, the constructs were sequenced with the
following primers:
Name Position Sequence 5’ – 3’
VKORC1 5’UTRi fw 3514- 3539
CCG CTC GAG TAG ATG TGA GAA ACA GCA
TCT GG
VKORC1 5’UTRi rv 5277- 5260 CCC AGG CTT AAA CCA GCC ACG GAG CAG
VKORC1 5’UTR1 rv 4080- 4961 CTT CCT CAC TTC TTC CTT GC
VKORC1 5’UTR4 rv 5025- 5006 GGG AAA TGA AGT CTC CAC AG
VKORC1 5’UTR2 fw 3924- 3938 CTG GGC GAC AGA GTG
VKORC1 5’UTR3 fw 4225- 4243 AGT GTA GAT GGG GAG GAT G
Sequencing was performed with the Big Dye® Terminator  v3.1  Cycle
Sequencing Kit with Big Dye® Terminator v3.1 Sequencing Buffer (5x) and
Big Dye® Terminator Mix. The Big Dye Terminator Mix contains
terminating nucleotides labelled with four different dyes, which makes a
differentiation between A, T, C and G possible.
For each sample 2 µl Sequencing Buffer (5x), 0,4µl Big Dye Terminator
Mix, 5pmol primer, 25ng plasmid DNA and ddH2O to reach a final volume
of 10µl, were pipetted into a 96- well reaction plate. The sequencing
reaction was carried out using a 9700 Perkin Elmer PCR Cycler. (Cycling
conditions: initial denaturation of 1 min at 96°C; 25 cycles with 10 sec
96°C, 5 sec 50°C and 4 min 60°C; storage at 4°C)
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Because of the length of the sequence of interest and the fact that the
sequence cannot be read immediately after the primer, six different
primers were used, which generate overlapping fragments. This way the
whole sequence of the plasmid could be read.
Purification of the sequencing reaction products
The sequencing reaction products were diluted with 25µl of injection
solution and transferred into a SEQ 96- well plate. Unused wells were
covered with sticky tape to avoid contaminations, so the other wells of the
same plate could still be used afterwards. The plate was put into a vacuum
exhaust and the injection solution was sucked off with a pressure of 20
mmHg by a vacuum pump until the wells were empty. 25µl injection
solution was added and the procedure was repeated. After this second
washing step, the purified sample was dissolved in 25µl injection solution
and transferred into a 96-well sequencing plate, which was covered with a
septum. Sequencing was performed on an ABI PRISM 3100 Genetic
Analyser, using a 3100 POP-6 polymere. The sequence was analyzed
with the SeqScape program.
2.6.Cell culture
2.6.1. Culture of osteoblasts
The cell line hFOB1 was delivered in a tube containing 7 x 106/ml. It was
processed according to the recommendations of the American Type
Culture Collection (ATCC). Originally, an incubation temperature of 34°C
was chosen because of the recommendations of ATCC.
Cells were thawed in a water bath at 37°C; 500µl of the cells were mixed
with 5 ml FBS and centrifuged at 1200 rpm for 5 min. The supernatant was
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discarded, the pellet was resuspended in 5 ml FBS, centrifuged again,
resuspended in 10 ml of complete growth medium (DMEM/F12 1:1 with
2.5mM L- glutamine, 15mM HEPES, 0.5mM sodium pyruvate, 1.2g/L
sodium bicarbonate, 0.3mg/ml G418 and 10% FBS without phenol red)
and cultivated in cell-culturing flasks at 34°C and 5% CO2. The medium
was changed every 2-3 days. As contaminations were observed when
using this medium, the composition of the medium was changed. The new
medium contained: DMEM/F12 1:1 without phenol red (with 2.5mM L-
glutamine, 15mM HEPES, 0.5mM sodium pyruvate, 1.2 g/L sodium
bicarbonate), 10% FBS, 100 U/ml penicillin G, 100 µg/ml streptomycin and
0.25 µg/ml fungizone.]
Cells were splitted depending on the confluence. The cells were washed
with ~ 5ml PBS followed by incubation with trypsin until all cells detached
from the bottom of the flask. By adding complete growth medium, the
trypsin was inactivated through FBS and the cells were centrifuged,
resuspended in complete growth medium and split into new flasks.
Freezing Cells for Storage
The medium was removed from the flask and the cells were washed with
PBS. By adding trypsin-EDTA the cells were detached from the bottom of
the flask, medium with FBS was added to inactivate trypsin, the cells were
centrifuged for 5 minutes at 1200rpm and the supernatant was removed.
The cells were then resuspended in icecold DMSO, placed at -80°C over
night and then put in liquid nitrogen for long term storage.
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2.7. Transfection of osteoblasts hFOB1
2.7.1. Transfection with Lipofectamine 2000
Osteoblasts hFOB1 were seeded into a 24- well plate with each well
containing 4 x 105 cells in 0.5 ml of medium without antibiotics. The cells
were incubated 24 hours prior to transfection at 34°C.
After 24 hours the Co-Transfection was carried out. For each sample 2µl
Lipofectamine 2000 was diluted with 48µl Opti-MEM and incubated at
room temperature for 5 min. Then, 25ng phRL-TK vector and 750ng pGL3
vector (basic, G or A) were diluted in 50µl Opti-MEM. The DNA and the
Lipofectamine solution were mixed to a total volume of 100µl and
incubated at room temperature for 20 min. The medium of the osteoblasts
seeded into a 24-well plate was renewed, 100µl of the DNA complex was
added to each well and the plate was incubated at 34°C for 48 hours. After
the transfection, the medium was removed and 100µl passive lysis buffer
per well were added. The cells were lysed under shaking for 15 min,
centrifuged at 13000 rpm for 1 min and stored at -20°C.
2.7.2. Transfection with Metafectene Pro
Metafectene Pro:
Metafectene Pro is a new transfection reagent, which was specifically
developed for moderately hard- or hard-to-transfect mammalian cell lines.
Its novel composition combines the RMA-Technology (“Repulsive
Membrane Acidolysis”) with a new TOP-Technology (Toxicity-Optimization
Module).
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Basic mechanism of intracellular gene transfer using cationic lipids:
When the cationic liposomes come into contact with DNA, a DNA-lipid
complex (=lipoplex) is formed. These lipoplexes are transferred through
the outer cell membrane by endocytosis and as a result lipoplex-
containing endosomes are formed within the endoplasm. These
endosomes possess H+-pumps, so the pumps are no longer able to
acidificate the endosomal lumen. This results in a relative low pH value
and high osmotic pressure, which breaks the endosomal membrane and
releases the lipoplexes into the cytosol. In case of plasmid DNA the
released genetic material must reach the nucleus and pass the nucleus
membrane. This is only possible during cell division when the nuclear
membrane opens, since plasmid DNA is not able to penetrate the
membrane by itself.
Repulsive Membrane Acidolysis (RMA):
This technology uses the acidic environment of the late endosomes to
weaken the membrane structure of the lipoplexes, which is achieved by a
protonable basic position near the lipophilic part of the cationic lipids.
Among these positively charged parts of the lipids, repulsive forces ease
the disruption of the endosomal membrane and thus the release of the
genetic material, so a high concentration of naked DNA is present in the
cytosol.
Toxicity Optimization Module (TOP):
The toxicity optimization module moderately destabilizes the DNA-lipid-
complex and potentiates the access for the RMA. Furthermore, it
decreases the toxic effects in transfection technology, which is essential
for in-vivo applications.
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The combination of both techniques -RMA and TOP- ensures the required
release of genetic material in the cytoplasma and the availability of enough
genetic material for uptake into the cell nucleus.
Transfection:
For each well 100µl of Opti-MEM and 1µl of Metafectine Pro were mixed
and incubated for 15 min at room temperature.
The osteoblasts were seeded in a 24-well plate. Each well contained 4x
105 cells in 0.5 ml of media without antibiotics and serum.
Per well 1µg of the pGL3 constructs (empty vector, G or A plasmid), 25ng
phRL-TK vector or 0.5µg GFP were mixed with the diluted lipid reagent
and were incubated for 15 min at room temperature. phRL-TK was added
as a negative control and GFP as a control for the transfection. 100µl of
the lipid - DNA mix was added to each well of the plate containing the cells
and incubated at 37°C. After 4 hours 0.5 ml of media with 20% FBS were
added per well, so the final concentration of FBS in one well was 10%.
After 16-24 hours the fluorescence of GFP was examined, in order to see
if the transfection has worked.
After 48 hours the transfection medium was removed and the cells were
lysed under shaking with 100µl passive lysis buffer per well. After 15 min
the lysate was centrifuged at 13000 rpm for 1 min and stored at -20°C.
2.8. Dual Luciferase Reporter Gene Assay
The Dual Luciferase Reporter Assay was carried out with the Luminometer
Lucy2 (Fa Anthos). The Dual Luciferase Reporter Assay is based on the
simultaneous expression and measurement of two individual reporter
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enzymes within a single system. The “experimental” reporter is correlated
with the specific conditions of the experiment, while the co-transfected
“control” reporter represents the baseline response. The activity of the
experimental reporter is normalized to that of the internal control, which
minimizes experimental variability, caused by differences in cell viability or
transfection efficiency. Moreover variability through cell lysis efficiency and
assay efficiency can be eliminated
The VKORC1- promoter in the plasmid- constructs pGL3-G and pGL3-A
induces the activity of the Firefly luciferase, which is normalized by the
Renilla luciferase coded in the phRL-TK vector. In my experiments, the
pGL3-basic vector was used as a negative control. It does not contain the
promoter sequence and as a consequence shows no luciferase activity.
The luciferase assay reagent (LAR II) and the Stop & Glo solution were
prepared according to the introductions of the manufacturer (Promega).
For the assay 20µl of each sample were transferred into a 96-well plate,
which was placed into the luminometer. The luciferase activity of each well
was measured by firstly adding 100µl Luciferase assay reagent II (LAR II),
measuring the firefly luciferase activity and then immediately adding 100µl
Stop & Glo reagent to measure the Renilla luciferase activity. By adding
the Stop & Glo reagent, the luminescence signal of the firefly luciferase is
quenched and the Renilla luciferase reaction is initiated simultaneously.
2.9. Cloning of VKORC1 full length constructs
To produce a full length construct of VKORC1 the plasmids pGL3-G and
pGL3-A, containing the promoter sequence G and A, respectively, were
used. The luciferase gene located directly behind the promoter was
replaced by the coding sequence of the VKOR gene. In a first step, the
Materials and Methods
44
plasmids were digested with the restriction enzymes Hind III and Xba I to
release the luciferase gene. Then, the coding sequence of VKORC1 was
amplified with primers containing restriction sites for Hind III and Xba I.
The PCR product was treated with Hind III and Xba I and ligated with the
pGL3 plasmids. At last, the full length constructs were cloned into DH5?
cells which were produced by a fellow student, who provided them for my
diploma thesis.
2.9.1. RNA- Isolation
To obtain VKORC1 mRNA, the liver cell line HepG2 was used.
The RNA isolation was carried out with a RNeasy Mini Kit (QIAGEN).
HepG2 cells were lysed in PLB (passive lysis buffer) and 700 µl of this cell
lysate were spun through a QIAshredder spin column to homogenize the
cell lysate. After that, 700µl 70% ethanol was added and mixed by
pipetting. 700µl of this solution was transferred into a RNeasy spin column
placed in a 2 ml collection tube, centrifuged for 30 sec at 13200 rpm, so
the total RNA was bound to the membrane of the spin column. The flow-
through was discarded. To wash the spin column membrane, 700µl of
buffer RW1 was added, centrifuged for 30 sec at 13200 rpm and the flow-
through was discarded again. Following this, the spin column was washed
twice with 500µl of buffer RPE for 30 sec at 13200 rpm.
To eliminate any possible carryover of residual buffer RPE or flow-through,
the spin column placed in a 2ml tube was centrifuged for additional 2 min
at 13200 rpm and transferred into a new 1.5ml tube. 50µl RNase free
water was added to the spin column, incubated for 10 min at room
temperature and centrifuged for 1 min at 13200 rpm to elute the RNA,
which was immediately put on ice and stored at –80°C.
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To determine the amount of isolated RNA, the optical density was
measured with NanoDrop® ND- 1000 Spectralphotometer (PEQLAB)
2.9.2. cDNA- Synthesis
An aliquot containing 1ng RNA was incubated for 10 min at 70°C and
immediately put on ice. A mastermix was prepared as follows: 10.75µl of
the Premix containing 5µl 5x Buffer, 1.25 µl dNTP Mix (20 mM/dNTP), 2µl
Oligo- desoxy- Thymin Primer (= oligo dT; 10 pmol/µl)) and 2.5µl DTT
(100mM) per sample were mixed with 1µl RNA Guard (23.7 U) and 1µl
MMLV- RT (8 U/µl). 12.5 µl of this master mix were added to the RNA and
incubated for 10 min at 22°C, followed by 45 min at 37°C and at finally for
3 min at 99°C. The samples were cooled down on ice and 37µl of ddH2O
were added.
2.9.3. Quality control of cDNA by control gene PCR
As a quality control of cDNA synthesis, the housekeeping gene GAPDH
was amplified by PCR. This PCR allows to verify, that a suitable amount
and of cDNA in appropriate quality was generated.
The Mastermix contained the following reagents per sample: 2µl 10x PCR-
Buffer II without MgCl2 (25mM), 0.8µl Rapid Load PCR Loading Dye, 0.2
µl dNTP Mix (20 mM/base), 0.17 µl AmpliTaq Gold (5 U/µl), 1 ?l primer
GAPDH fw (10 pmol/?l), 1 ?l primer GAPDH rv (10 pmol/?l) and 14.8 µl A.
bidest. To 20 µl of the master mix 2 µl of undiluted DNA (=cDNA) were
added.
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Gene Primer Sequence 5’ – 3’
Gap- f GAA GGT GAA GGT CGG AGT C
GAPDH
Gap- r GGG GAT GGT GAT GGG ATT TC
Temperature protocol:
Initial denaturation 95°C 7 min
95°C 30 sec
60°C 30 sec38 cycles
72°C 30 sec
Final elongation 72°C 10 min
Storing 4°C -
Electrophoresis:
Seven µl of the PCR products and 3.5 µl marker (1x TBE marker) were
loaded on a 5 % criterion gel.
Running conditions: 1x TBE buffer at 175 V for 45 minutes.
2.9.4. Generation of cDNA with restriction sites
To be able to ligate the cDNA of VKORC1 into a vector, which contains
restriction sites for the endonucleases Hind III and XbaI, these restriction
sites have to be attached to the ends of the cDNA. The Hind III restriction
site was attached to the 5’ end of the forward primer, directly in front of the
start codon and the restriction site of XbaI was placed directly behind the
stop codon of the coding sequence of the VKORC1 gene.
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Primer Sequence 5’ – 3’ Length
#182 VKORC1cdsfw AAG CTT ATG GGC AGC ACC TGG G 21 bp
#183 VKORC1cdsrv TCT AGA TCA GTG CCT CTT AGC CTT GCC 27 bp
A master mix was prepared, containing the following amounts of reagents
per sample: 2µl PfuUltra HF reaction buffer (10x), 1µl VKORC1cds fw
(10pmol/µl), 1µl VKORC1cds rv (10 pmol/µl), 0.2µl dNTP (20mM), 0.5µl
PfuUltra Hotstart DNA Polymerase and 100ng of cDNA. In order to reach
the final reaction volume of 20µl, an appropriate amount of ddH2O was
added.
Temperature protocol:
Initial denaturation 94°C 10 min
94°C 45 sec
60°C 45 sec35 cycles
72°C 2 min
Final elongation 72°C 7 min
Storing 4°C -
Electrophoresis:
Sample: 3.5 µl of a 1x TBE marker and 7 µl of the PCR product
Gel: 5% criterion polyacrylamide gel
Running conditions: 1x TBE at 175V for 45 minutes.
The chosen 5’-primer was able to bind not only at the 5’ site of the cDNA,
but also within the cDNA sequence. Thus, a PCR product 120bp shorter
than the full length coding sequence of the VKOR gene was generated in
addition to the full length fragment. As it was not possible to design a
primer with no homology, it was necessary to separate both fragments by
electrophoresis followed by elution from the gel.
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Isolation of the full length VKOR cDNA construct
The two different products were separated by electrophoresis on an
agarose gel (0.8% agarose gel; 1x TBE, 100V, 60min). The band, which
corresponds to the PCR product of full length cDNA of VKORC1, was cut
out of the gel and the DNA was extracted using a QIAGEN gel extraction
kit.
The QIAquick Gel Extraction Kit contains following reagents: Buffer QG,
Buffer PE and Buffer EB. The excised gel slice was weighed, 3 volumes of
buffer QG were added to 1 volume of gel slice (100mg ~ 100µl) and
incubated at 50°C for 10 minutes until the gel slice had completely
dissolved. Then, 1 gel volume of isopropanol was added and mixed. To
bind the DNA to the spin column, the sample was applied to a QIAquick
spin column and centrifuged for 1 min at 13000 rpm. The flow-through was
discarded. To wash the bound DNA, 750µl of Buffer PE were added to the
spin column and again centrifuged for 1 min at 13000 rpm. To remove
residual ethanol from buffer PE, the spin column was centrifuged at 13000
rpm for an additional 1 min. To elute the DNA, the column was placed in a
1.5 ml tube, 30 µl of Buffer EB were added to the center of the membrane.
After 1min incubation at room temperature, the column was centrifuged for
1 min at 13000 rpm.
2.9.5. Restriction digestion of the plasmids pGL3-G,
              pGL3-A and the VKORC1 PCR product
To linearise the plasmids and to remove the luciferase gene from the
plasmids prior to ligation with the VKORC1 full length construct, the
plasmids pGL3-G and pGL3-A were double digested with the restriction
enzymes HindIII and XbaI. The full length PCR fragment of the VKORC1
coding sequence was also digested with the same enzymes.
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For the restriction digestion, an enzyme mix containing 25µl Buffer B
(10x), 1µl HindIII (1U/µl) and 1µl XbaI (1U/µl) was prepared. Then, 2.5µl of
the enzyme mixwere mixed with 1µg pGL3-G or pGL3-A or 120ng PCR
product and an appropriate amount of A. bidest to reach a final reaction
volume of 25µl. The restriction mix was incubated at 37°C for 1 hour and
the results were examined on a 0.8% agarose gel (running conditions: 1x
TBE, 100V, 60min). The linearised plasmids were excised of the gel and
extracted with the QIAquick gel extraction kit.
2.9.6. Ligation of the VKORC1 PCR product into the
          plasmids
The  double digestion of the vector plasmids and the insert PCR product of
the VKORC1 gene should support insertion of the sequence of interest
into the vector in the correct orientation.
The ligation was performed using the rapid DNA ligation & transformation
kit (Fermentas).
For the ligation reaction 70 ng plasmid DNA, 40ng VKORC1 PCR product,
4µl 5x Rapid Ligation Buffer and 1µl T4 DNA Ligase (5U) were mixed and
incubated for 5 minutes at 22°C.
The ligation product was examined on an 0.8% agarose gel at 100V for 90
min and stored at -20°C.
2.9.7. Transformation of the VKORC1 full length construct
            into DH5? cells
The ligation product and the cells were thawed on ice. Then, 5µl of the
ligation product were added to 50µl of cells and incubated under shaking
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at 37°C for 10 minutes. Afterwards the cells were plated on prewarmed LB
agar plates containing 100µg/ml ampicillin and incubated for 12 – 16 hours
at 37°C.
Of each construct (pGL3-A and pGL3-G) five colonies were picked,
inoculated in 2 ml LB media and again incubated under shaking at 37°C
over night. Of 1.5ml of the liquid culture plasmid DNAs were isolated with
the QIAgen Spin Miniprep Kit according to the recommendations of the
manufacturer and as described in section II.2.2.
2.10. Analysis of the isolated VKORC1 full length
        plasmids
2.10.1. Restriction digestion
To verify, that the isolated plasmids contained the insert, three different
digestion reactions were carried out. One with the enzymes Hind III and
Xba I to release the insert, one with the enzyme Hind III and one with the
enzyme Xba I only.
For the double digestion 2.5µl enzyme mix (25µl 10x Buffer B + 10 U Hind
III + 10 U Xba I) and ~ 800ng plasmid DNA were mixed. Water was added
to reach the final reaction volume of 25µl.
For the reactions with only one enzyme, 1µl of Hind III or Xba I,
respectively, ~800ng plasmid DNA and water were mixed. The final
reaction volume was 25µl.
The three samples were incubated at 37°C for one hour and analyzed on
0.8% agarose gel. Running conditions: 1x TBE, 100V, 60 minutes.
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2.10.2. PCR
Three PCR reactions were carried out with primer pairs listed below. (a)
for the full length fragment (fragment of interest) containing the promotor
and the insert, which should be located adjacently (b) for the insert
fragment and (c) for the promotor sequence only.
Used primers:
Primer Sequence 5’-3’
VKORC1 cds fw AAG CTT ATG GGC AGC ACC TGG G
VKORC1 cds rv TCT AGA TCA GTG CCT CTT AGC CTT GCC
VKOR -1639 C-F ACA GTA AGG GAT CCC TCT GGG AAG TC
VKOR -1639 W-R AGG CGT GAG CCA CCG CAA CC
VKOR -1639 M-R AGG ATT ATT AGC GTG AGC CAC CGC TCC T
The mastermixes were prepared as follows:
a) 2µl 10x PCR Buffer II without MgCl2, 1.5µl MgCl2 (25mM), 0.8µl
Rapid Load PCR Loading Dye, 0.2µl dNTP Mix (20 mM/base), 0.1µl
AmpliTaq Gold (5U/µl), 0.4?l primer VKOR -1639C-F (10pmol/?l),
??l primer VKORC1 cds rv (10pmol/?l), 1µl plasmid DNA and
12.4µl A. bidest.
b) 2µl 10x PCR Buffer II without MgCl2, 1.5µl MgCl2 (25mM), 0.8µl
Rapid Load PCR Loading Dye, 0.2 µl dNTP Mix (20 mM/base), 0.1
µl AmpliTaq Gold (5U/µl), 1?l primer VKORC1 cds fw (10pmol/?l),
??l primer VKORC1 cds rv (10pmol/?l), 1µl plasmid DNA and
12.4µl A. bidest.
c) 2.5µl 10x PCR Buffer II without MgCl2, 1.5µl MgCl2 (25mM), 0.8µl
Rapid Load PCR Loading Dye, 0.25µl dNTP Mix (20mM/base), 0.1
µl AmpliTaq Gold (5U/µl), 0.5?l primer VKOR -1639W-R (10
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pmol/?l), 0.4?l primer VKOR -1639C-F (10pmol/?l), 0.08µl VKOR
-1639 M-R (10pmol/µl), 1µl plasmid DNA and 12.4 µl A. bidest.
Temperature protocol for all three PCR reactions:
Cycling conditions
Time Grade Cycles
10' 94 1
45'' 94
45'' 60 35
2' 72
7' 72 1
~ 4
Electrophoresis:
3.5µl MspI marker and 7µl of the PCR product were loaded on a 5%
criterion gel. Running conditions: 1x TBE, 175V, 45 minutes.
2.10.3. Sequencing
To verify the sequence of the plasmid construct, the plasmid DNA was
sequenced with three different primers. A primer complimentary to the  5’-
end of the promotor, to verify that the coding sequence of VKORC1 was
inserted adjacent to the promoter. Two primers complementary to the 3’
and 5’ end of the insert to test whether the correct sequence of the insert
was present.
Name Sequence 5’ – 3’
VKORC1 cds fw aag ctt atg ggc agc acc tgg g
VKORC1 cds rv tct aga tca gtg cct ctt agc ctt gcc
VKORC1 5’UTR 5fw tgg ctg ttt tcc taa ctc
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For each primer a mastermix was prepared as follows:
2µl Sequencing Buffer (5x), 0.4µl Big Dye Terminator Mix, 1µl primer
(5pmol/µl),  25ng plasmid DNA and water to reach a final  volume of  10µl.
The sequencing reaction was carried out in a 9700 Perkin Cycler. The
purification of the sequencing reaction products and the analysis were
performed as described in 2.6. and 2.7.
PCR conditions:
1' 96°C 1x
10'' 96°C
5'' 50°C
4' 60°C
25
Hold 4°C ~
2.10.4 Digestion with EXO SAP-it
To remove unspecific products and reduce back ground noise during
sequencing the PCR products were digested with EXO SAP-it prior to
sequencing.
Two µl EXO SAP-it were added to 10µl PCR product followed by
incubation for 30 minutes at 37°C and 15 minutes at 80°C.
The sequencing reaction was carried out with the same primers and
temperature protocol as described in 2.10.3. Purification and analysis of
the sequencing reaction products were performed as described in 2.6. and
2.7.
Results
54
III. RESULTS
1.Restriction digestion of the plasmids pGL3-G and pGL3-A
Some of the plasmid DNAs isolated from the glycerol stocks showed an
insert with double the length than expected. This may indicate that in
some vectors two promoter fragments were inserted in tandem fashion.
These bacterial cells were discarded. For all further experiments only
plasmids with the correct length of the insert were used.
2. Sequencing of the plasmids pGL3-G and pGL3-A
Resequencing of the promoter constructs, pGL3-A and pGL3-G, showed
the correct sequence of the promoter with an A nucleotide and a G
nucleotide, respectively, at the position -1639.
3. Dual Luciferase Reporter Assay
The results of the dual luciferase reporter gene assay, either of
Lipofectamine 2000 or Metafectene Pro transfections, are listed in table 1
and 2. Table 1 shows the results of the transfection of the osteoblasts
hFOB1 with Lipofectamine 2000. The transfections were performed on two
different days with four replicas per construct. The results of the first
transfection shows an average luciferase activity of 8.9 for the pGL3-G
construct and 14.0 for the pGL3-A construct. During the second
transfection much higher luciferase activity values were obtained with an
average luciferase activity of 14.4 for the pGL3-G construct and 159.9 for
the pGL3-A construct.
The results of the transfections with Metafectene Pro are listed in table 2.
These transfections were performed on four different days with four
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replicas per construct. The average luciferase activity for the pGL3-G
construct was 3.3, 3.8, 3.5 and 5.7. For the pGL3-A construct the average
luciferase activity was 2.5, 2.7, 2.7 and 3.4. The variation between
transfections was much lower than observed for Lipofetamine.
Table 3 shows the mean values of the four transfection experiments with
Metafectene Pro for the pGL3-G and pGL3-A constructs, with a mean
value of 4.1 for pGL3-G and 2.85 for pGL3-A.
3.1. Results of the dual luciferase reporter gene assay
Transfection with Lipofectamine 2000:
No
treatment
pGL3
basic
pGL3-G pGL3-A
-0,009 0,033 8,823 9,501
-0,008 0,021 7,438 14,462
-0,013 -0,006 11,873 17,096
-0,021 0,025 7,475 15,088
8,90225 14,0368
-0,005 1,578 20,327 84,109
0,002 0,694 9,624 188,151
0 2,191 5,084 142,261
0,005 0,822 22,502 225,309
14,3843 159,958
                               Table 1. Results of the Dual luciferase reporter gene assay
                                             Transfection of osteoblasts with Lipofectamine 2000
The results of the reporter gene assay following Lipofectamine 2000
transfection of osteoblasts were poorly reproducible and were considered
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inadequate for both constructs. The luminescence values differed highly
between transfections, as shown in figure 7.
pGL3-G pGL3-A
Vector
0,000
50,000
100,000
150,000
200,000
R
LU
n=8 n=8
Transfection with Lipofectamine
                      Fig. 7. Transfection with lipofectamine shows inconsistent efficiency
Figure 7 illustrates the high variation in the transfection efficiency with
lipofectamine 2000. The values for pGL3-G vary between 7 RLU (relative
luminescence unit) and 22 RLU, in contrast the values of pGL3-A vary
between 9 RLU and 225 RLU. In one experiment, the difference between
luciferase activity induced by the promoter element pGL3-A was
comparable to the activity induced by pGL3-G, in the second experiment
pGL3-A induced much higher luciferase activity.
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Transfection with Metafectene Pro
no treatment pGL3 basic pGL3-G pGL3-A
-0,001 0,026 4,052 2,426
0,005 0,025 2,792 2,62
-0,002 0,035 2,694 2,971
-0,001 0,015 3,655 2,035
3,29825 2,513
0 0,04 5,122 2,919
0,003 0,014 5,091 2,627
0,001 0,018 1,712 1,285
0,004 0,004 3,466 3,931
3,84775 2,6905
0,001 0,011 2,636 1,78
0,003 0,015 1,879 4,85
0,003 0,008 6,758 2,176
0,004 0,013 2,938 2,25
3,55275 2,764
-0,001 0,026 7,942 2,468
0,002 0,012 2,596 4,233
0,002 0,023 2,744 1,159
-0,002 0,011 9,522 5,9
5,701 3,44
                      Table 2. Results of the Dual luciferase reporter gene assay
Transfection of osteoblasts with Metafectene Pro
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The table shows results of transfection of osteoblasts with Metafectene
Pro on 4 different days with four replica per construct. The values of the
average luciferase activity lie between 3.3 RLU and 5.7 RLU for the pGL3-
G construct and between 2.5 RLU and 3.4 RLU for the pGL3-A construct.
In contrast to transfection with Lipofectamine the luciferase activity was
higher in the pGL3-G promoter construct than in the pGL3-A construct in
each transfection experiment, also shown in figure 8.
pGL3-G pGL3-A
Vector
2,000
4,000
6,000
8,000
R
LU
A
A
n=16 n=16
Transfection with Metafectene
                   Fig. 8. Results of the dual luciferase repoter gene assay
                               Transfection of osteoblasts with Metafectene Pro
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Lipofectamine 2000 Metafectene Pro
Transfection
0,000
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100,000
150,000
200,000
R
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A
AA
A
A
A
A
AA
A
pGL3-A
     Fig. 9. Comparison between the two trans-
     fection methods in osteoblasts with the pGL3-
     G plasmid
Lipofectamine 2000 Metafectene Pro
Transfection
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10,000
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20,000
R
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A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
pGL3-G
     Fig. 10. Comparison between the two trans-
     fection methods in osteoblasts with the pGL3-A
     plasmid
Figures 9 and 10 demonstrate the high variation of the luminescence
following transfections with Lipofectamine 2000 compared to transfections
with Metafectene Pro.
Plasmids Mean Median
pGL3-G 4,0999 3,2020
pGL3-A 2,8519 2,5440
Table 3. Median and mean values for the pGL3-G and pGL3-A plasmids of all
                                transfections with Metafectene Pro
The mean values of the transfection with Metafectine Pro demonstrate a
43% higher expression in osteoblasts containing the pGL3-G plasmid
compared to osteoblasts containing the pGL3-A vector, illustrated in figure
11.
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          Fig. 11. Relative luciferase activity measured in osteoblasts transfected with
                       Metafectine Pro
4. Cloning of VKORC1 full length constructs
4.1.Generation of cDNA of the VKORC1 coding region
       containing restriction sites
The results – generation of two PCR products instead of one - indicated
that the selected VKORC1 cds primers bind not only to the expected
binding site but also to another sequence within the cDNA. The longer
fragment with 506 bp length represents the cDNA containing the two
restriction sites. The second fragment with a length of approximately
400bp was identified as a product corresponding to a fragment of the
cDNA generated by the binding of the VKORC1 cds fw primer to a
homologous sequence located approximately 120 bp downstream of the
start codon within the cDNA.
Several modifications regarding temperature and primer concentrations
did not eliminate the generation of the second PCR product (Fig.12). To
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proceed with cloning, the correct band had to be separated by  gel
electrophoresis and the DNA had to be eluted from the gel. This DNA
extraction product was used for all following experiments.
Marker
622
527
404
307
               Fig. 12. Coding region of VKORC1 with restriction sites
                            Slot 1: Marker pBR322 DNA MspI-digest, Slot 2+3+4: Insert with restriction sites
4.2. Introduction of the VKORC1 coding region into the
       pGL3-G and pGL3-A plasmids
Figure 13 shows the results of the ligation of the VKORC1 coding region
into the pGL3-G and pGL3-A plasmids. Slot 2 and slot 6 depict the full
length constructs containing either pGL3-G or pGL3-A. The full length
constructs were compared to the digested full length plasmids pGL3-G
and pGL3-A (digestion with both endonucleases XbaI and HindIII). This
double digestion was performed to cut out the inserted coding region of
VKORC1, giving 2 fragments on the gel. A longer fragment which
represents the linearised pGL3-G or pGL3-A and a shorter fragment
representing the VKORC1 coding region  (slot 3 and 7 of figure 13). The
shorter fragment, which should correspond to the  VKORC1 coding region,
migrated with approximately 1800bp – which is 3 times longer than the
actual length of 506bp (PCR fragment corresponding to the coding
region). This indicated that the insertion of the coding region segment of
VKORC1 into the plasmids did not occur correctly.
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Marker
10000
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  2000
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    500
            Fig. 13. Control of the full length plasmids pGL3-G and pGL3-A
                Slot 1: Marker: FastRulerTMDNA Ladder High Range, Slot 2: undigested pGL3-G plasmid,
Slot 3: plasmid restricted with XbaI and HindIII, Slot 4+5: linearised pGL3-G digested with
                either XbaI or HindIII, Slot 6: undigested pGL3-A plasmid, Slot 7: plasmid restricted with
                XbaI and HindIII, Slot 8+9: pGL3-A linearised with either XbaI or HindIII
5. Analysis of the VKORC1 constructs
The generated full length plasmids were examined by PCR and
sequencing.
5.1. PCR
The results of the PCRs are shown in figure 14, 15 and 16.
All three PCR amplifications worked and generated products. In figure 15
and 16 the bands corresponding to the promoter and the insert are shown
to migrate with the correct length. In contrast, with primers spanning the
promoter and the cDNA sequence (figure 14), the expected fragment of
~2.2 kb was not generated.
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 Fig. 14                                        Fig. 15                                                        Fig.16
Figure 14: Lane 1 shows the marker pBR322 DNA MspI-digest with
fragment length of 622bp, 527bp, 404bp and 307bp. Lane 2 and 3 show
PCR products containing two fragments. One at the very top of the picture
that is not in the range of the marker anymore and a second fragment of
approximately 300bp. According to the position of the primers, one
fragment of 2.2kb should have been generated. This fragment was
supposed to contain the promoter and the coding region of the VKORC1
gene and should demonstrate that the coding region of VKORC1 was
integrated into the plasmid directly behind the promoter. According to
these results, this was obviously not the case.
Figure 15 shows the PCR product corresponding to the coding region of
VKORC1 with ~500bp. The first lane contains the marker  (pBR322 DNA
MspI-digest with fragments of 622bp, 527bp, 404bp and 307bp). Lane 2
and 3 show the PCR product. The longer fragment represents the coding
region of VKORC1 and the shorter fragment corresponds to the shorter
cDNA fragment generated by the annealing of the primer to the
homologous cDNA sequence (explained in III.4.1).
Figure 16 shows the PCR products of the promoter variants -1639G and -
1639A. Lane 1 shows the marker pBR322 DNA MspI-digest with
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fragments of 160bp, 147bp, 123bp, 110bp, 90bp. Lane 2 shows the
fragment corrsponding to the G allele fragments with a length of 82bp and
lane 3 shows the fragment corrsponding to the A allele fragment with a
length of 88bp.
The results indicate that the full length plasmids pGL3-G and pGL3-A
contain the promoter as well as the inserted coding region of VKORC1 as
intended, but also another sequence element.
5.2. Sequencing
The sequences obtained with the 5’ UTR fw primer showed, that the
promoter sequence was not followed by the coding region of VKORC1 as
was planned, but by segments of the luciferase gene. However, the
sequence of the luciferase gene was incomplete. The sequence segment
of the luciferase gene was followed by a sequence that could not be
identified using the chosen sequencing programm NCBI mega BLAST.
Surprisingly, the VKORC1 coding region was not found in the plasmid
construct by sequencing although a PCR product was generated when
using cDNA specific primers.
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IV. DISCUSSION
Osteocalcin is a protein which needs to be carboxylated to be active. The
carboxylation is vitamin K dependent and is carried out by
?-carboxylase, the enzyme that post translationally modifies the Gla-
residues of several proteins, among them osteocalcin. Following this
modification osteocalcin is activated and is then able to bind Ca2+. Bound
Ca2+ is incooperated in bone, which confers bone its hardness and
stability.
The -1639G>A polymorphism of the VKORC1 gene is the functional SNP
in VKORC1 [Wang et al 2008]. The A allele is associated with a decrease
of the promoter activity, resulting in lower mRNA expression compared to
the G allele [Geisen et al 2005]. This difference in mRNA expression has
been shown to partly explain the variability of warfarin sensitivy and dose
requirement of warfarin between different patients and different ethnic
populations. Patients with the genotype -1639AA are more warfarin-
sensitive and require the lowest doses of warfarin, whereas patients with
the genotype -1639AG or -1639GG require intermediate and high warfarin
doses, respectively [Yuan et al. 2005]. The variability of warfarin dose
requirement between different ethnic populations is due to different
frequencies of the genotype -1639AA in different ethnic populations [Wang
et al. 2008].
To my knowledge, the -1639G>A polymorphism was never investigated in
association with bone and osteoporosis. The aim of this study was to
collect information on the effect of the -1639G>A polymorphism on the
expression of VKORC1 in osteoblasts,.
In my thesis I investigated whether the -1639AA genotype of the
-1639G>A polymorphism decreases the promoter activity of VKOR in
osteoblasts as has been shown by Geisen et al. [2005] for liver cells.
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The transfection of the osteoblasts was performed with Lipofectamine
2000 as well as Metafectene Pro. The transfection with Lipofectamine was
performed on two different days with four replica in each experiment, but
the dual luciferase gene assay did not show stable results. This could be
due to the fact, that the transfection with lipofectamine was performed at
34°C, but the temperature at which luciferase is most active is 37°C. It is
possible that the low transfection temperature of 34°C influenced the
efficiency and reproducability of transfection with Lipofectamine followed
by the luciferase reporter gene assay. As only Wang et al. but no other
research groups reported difficulties in transfection of cells including
osteoblasts with Lipofectamine, a general problem of transfection with
Lipofectamine can be excluded. Wang transfected HepG2 cells with
Lipofectamine and measured the mRNA expression of the -1639G>A
polymorphism in a dual luciferase reporter gene assay, but got no reliable
results. The authors [2008] suggested that the transfection method with
Lipofectamine for the reporter gene assay is an inappropriate method for
detecting -1639G>A effects. Thus, it is possible that the problem is not the
transfection method with Lipofectamine but the detection of this particular
polymorphism with this method.
The results of the reporter gene assay of Metafectene transfected
osteoblasts were much more consistent, than with Lipofectamine
transfected cells, with significantly less variation within one transfection
experiment and only slight variation between transfections performed on
different days. The results of the reporter gene assay, following
transfection with Metafectene, showed that in osteoblasts the promoter
activity of the pGL3-G plasmid is 43% higher than the promoter activity of
the pGL3-A plasmid.
This suggests that in osteoblasts, the A allele of the
-1639G>A polymorphism is also associated with lower promoter activity of
VKORC1 as reported for HepG2 cells. The results are in line with the data
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reported by Yuan et al. [2005] who found a 44% higher promoter activity
for the -1639GG allele compared to the -1639AA allele. These results are
also in agreement with the studies of Geisen et al. [2005] and Wang et al.
[2008] who both tested the effect of the -1639G>A polymorphism in liver
cells.
In contrast, following lipofection with Lipofectamine the -1639A allele
carrying constructs induced a higher promoter activity, albeit these results
could only be observed in one of two experiments. Also, the differences
between the quadruplicates were highly variable and not reliable. I
assume, that the transfection method influences the results of the reporter
gene assay.
To find an association, if any, between the effect of the -1639G>A
polymorphism and osteoporosis, it would be necessary to prove that this
polymorphism has the same effect when the promoter drives the VKORC1
gene instead of the luciferase gene.
After I found that the -1639G>A polymorphism in VKORC1 also has an
effect in osteoblasts, I wanted to know if and how the promoter genotype
influences the VKORC1 expression in osteoblasts. I planned to investigate
a construct containing the VKORC1 promoter as well as the coding
sequence. The strategy that I chose was based on cloning the coding
region of VKORC1 into the plasmids that I already had which contained
the promoter of VKORC1 with either the G allele or A allele at the position
-1639. This strategy was not successful, because of problems during the
preparation of the construct. The first indication was the observation of
fragments with incorrect lengths as indicated by electrophoretic analyses
of the construct. Analysis of the construct by sequencing showed that the
promoter of VKORC1 is not followed by the coding region of VKORC1 but
by a segment of the luciferase gene. The VKORC1 coding sequence could
not be found by sequencing, instead, a sequence that was not assignable
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was found directly following the luciferase fragment. Obviously the double
digestion of the pGL3 plasmids, to cut out the luciferase gene, failed and
that prevented the insertion of the coding region of VKORC1 into the
pGL3-A and pGL3-G plasmids.
Due to time constraints, it was not possible for me to try another method to
successfully produce a full length construct, which would be needed to be
able to analyse the effect of the -1639G>A polymorphism on osteocalcin in
osteoblasts.
The research group around Wang [2008] managed to produce a full length
construct of VKORC1, proceeding differently. In contrast to my study, they
cloned the whole VKORC1 gene into the pGL3-G and pGL3-A vector, and
this approach was successful. Thus, the strategy chosen by Wang et al
maybe the appropriate way to obtain a full length construct.
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